10x Genomics, Inc. (TXG) Stock Analysis
A live, multi-source view of 10x Genomics, Inc. (TXG): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides.
Sector: Healthcare · Industry: Medical Devices · United States · 1,178 employees · 10xgenomics.com
Key statistics · as of 2026-09-06
As of 2026-09-06, 10x Genomics, Inc. (TXG) had a market capitalization of $8.16B (forward 308.1) and a beta of 2.08; the shares traded in a 52-week range of $11.16 – $66.94 (349.7% over the year).
- Market cap
- $8.16B
- Enterprise value
- $7.69B
- Forward P/E
- 308.1
- Price / book
- 9.92
- EPS (trailing)
- $-0.60
- EPS (forward)
- $0.20
- Payout ratio
- 0.0%
- 52-week range
- $11.16 – $66.94
- 52-week change
- 349.7%
- Beta
- 2.08
- Average volume
- 3.1M
- Shares outstanding
- 120.2M
- Short % of float
- 17.93%
- Profit margin
- -12.2%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, 10x Genomics, Inc. (TXG) last closed at $66.38 (the last completed close before that scan).
Technicals at the scan: RSI 65 (neutral territory), price +6.4% versus its 20-day average, 20-day versus 50-day average spread +18.6%, MACD histogram -0.26.
Sentiment inputs: 75% of recent Finnhub-scored headlines read bullish; StockTwits 78% bullish; analyst consensus score 60/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of TXG; corporate insiders filed 0 buys and 15 sells (6 distinct filers, latest disclosure 2026-09-08). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: John R. Stuelpnagel (0B/5S), Serge Saxonov (0B/4S), Shehnaaz Suliman (0B/2S), Sarah A. Teichmann (0B/2S), Benjamin J. Hindson (0B/1S), Adam Taich (0B/1S). Who is trading what
RapidTradeView pick record
TXG has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls 10x Genomics, Inc. (TXG) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell TXG.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.